In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 288-14-2, name is Isoxazole, introducing its new discovery. Product Details of 288-14-2
The advent of large-scale NMR-based screening has enabled new strategies for the design of novel, potent inhibitors of therapeutic targets. In particular, fragment-based strategies, in which molecular portions of the final high-affinity ligand are experimentally identified prior to chemical synthesis, have found widespread utility. This chapter will discuss some of the practical considerations for identifying and utilizing these fragment leads in drug design, with special emphasis on some of the lessons learned from more than a decade of industry experience. Copyright 2005, Elsevier Inc. All rights reserved.
We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 288-14-2, and how the biochemistry of the body works.Product Details of 288-14-2
Reference：
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem